Sodium phenylbutyrate and taurursodiol

(Relyvrio)

Sodium phenylbutyrate and taurursodiol

Drug updated on 11/15/2023

Dosage FormSuspension (oral; sodium phenylbutyrate/taurursodiol: 3g/1g)
Drug ClassUnknown mechanism of action
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Relyvrio (sodium phenylbutyrate and taurursodiol)2022Amylyx Pharmaceuticals, Inc, Cambridge, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Managed care considerations to improve health care utilization for patients with ALS. 2023American Journal of Managed Care